NCT01753570 - Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Chronic Hepatitis C(CHC)

Interventions

DRUG

MP-424

MP-424: 750mg every 8 hours (q8h) for 12 weeks

DRUG

RBV(24 weeks)

RBV: 600 - 1000mg/day based on body weight for 24 weeks

DRUG

IFN beta(24 weeks)

IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks

DRUG

RBV(48 weeks)

RBV: 600 - 1000mg/day based on body weight for 48 weeks

DRUG

IFN beta(48 weeks)

IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks

Trial Locations (1)

Toranomon Hospital, Kawasaki